Researchers at the University of Michigan have identified a 15-gene signature that may predict the likelihood of kidney cancer recurrence post-treatment. This advancement aims to personalize patient care by distinguishing those who might benefit from additional therapy from those who may not require it, moving beyond the traditional “one-size-fits-all” approach.
In related developments, Fox Chase Cancer Center has introduced a prognostic model that considers all kidney cancer histologies, with tumor histology emerging as a significant predictor of disease-free survival. Additionally, Cleveland Clinic researchers have identified a novel gene signature to assess recurrence risk in clear cell renal cell carcinoma, the most common kidney cancer subtype. Click for More Details
